-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Russell Investments Group Ltd. Sells 18,425 Shares of FibroGen, Inc. (NASDAQ:FGEN)
Russell Investments Group Ltd. Sells 18,425 Shares of FibroGen, Inc. (NASDAQ:FGEN)
Russell Investments Group Ltd. lessened its position in FibroGen, Inc. (NASDAQ:FGEN – Get Rating) by 12.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 127,964 shares of the biopharmaceutical company's stock after selling 18,425 shares during the quarter. Russell Investments Group Ltd. owned 0.14% of FibroGen worth $1,537,000 at the end of the most recent reporting period.
Several other institutional investors have also recently made changes to their positions in FGEN. Allspring Global Investments Holdings LLC bought a new stake in shares of FibroGen in the 4th quarter worth about $530,000. DekaBank Deutsche Girozentrale increased its stake in FibroGen by 3.7% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 27,950 shares of the biopharmaceutical company's stock worth $397,000 after buying an additional 1,000 shares during the period. Virginia Retirement Systems ET AL purchased a new position in FibroGen in the 4th quarter worth about $141,000. Advisor Group Holdings Inc. increased its stake in FibroGen by 90.6% in the 4th quarter. Advisor Group Holdings Inc. now owns 8,909 shares of the biopharmaceutical company's stock worth $130,000 after buying an additional 4,236 shares during the period. Finally, Toronto Dominion Bank purchased a new position in FibroGen in the 4th quarter worth about $1,835,000. Institutional investors own 77.35% of the company's stock.
Get FibroGen alerts:FibroGen Stock Performance
NASDAQ FGEN opened at $14.33 on Thursday. The company has a market capitalization of $1.34 billion, a price-to-earnings ratio of -6.05 and a beta of 0.87. The company's 50-day simple moving average is $11.99 and its two-hundred day simple moving average is $12.00. FibroGen, Inc. has a one year low of $7.81 and a one year high of $16.91.
FibroGen (NASDAQ:FGEN – Get Rating) last issued its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.94) by $0.16. FibroGen had a negative net margin of 83.64% and a negative return on equity of 100.51%. The firm had revenue of $29.81 million for the quarter, compared to the consensus estimate of $36.15 million. During the same quarter in the previous year, the firm earned ($1.45) EPS. The company's quarterly revenue was up 22.3% compared to the same quarter last year. Equities analysts expect that FibroGen, Inc. will post -3 earnings per share for the current fiscal year.Analyst Ratings Changes
Several research firms recently commented on FGEN. Cowen raised their price target on shares of FibroGen to $14.00 in a research note on Monday. The Goldman Sachs Group reduced their price target on shares of FibroGen from $9.00 to $8.00 and set a "sell" rating on the stock in a research note on Tuesday, May 24th. Finally, StockNews.com downgraded shares of FibroGen from a "buy" rating to a "hold" rating in a research report on Wednesday, August 10th.
About FibroGen
(Get Rating)
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Featured Articles
- Get a free copy of the StockNews.com research report on FibroGen (FGEN)
- Which Semiconductor Stocks Are Ready For Big Price Moves?
- Miners Advance On Earnings Despite Broader Economic Challenges
- Lowe's Stands Out Amid Q2 Retail Reports
- Agilent Technologies Proves Its Worth VS Illumina
- Target's Results Cap Upside Potential For Retail Stocks
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.
Russell Investments Group Ltd. lessened its position in FibroGen, Inc. (NASDAQ:FGEN – Get Rating) by 12.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 127,964 shares of the biopharmaceutical company's stock after selling 18,425 shares during the quarter. Russell Investments Group Ltd. owned 0.14% of FibroGen worth $1,537,000 at the end of the most recent reporting period.
羅素投資集團有限公司(Russell Investments Group Ltd.)最近向美國證券交易委員會(Securities And Exchange Commission)提交的13F文件顯示，該公司在第一季度減持了12.6%的FibroGen，Inc.(FGEN-GET評級)。該基金在本季度出售了18,425股後，持有這家生物製藥公司的127,964股股票。截至最近一個報告期末，羅素投資集團有限公司擁有FibroGen公司0.14%的股份，價值1,537,000美元。
Several other institutional investors have also recently made changes to their positions in FGEN. Allspring Global Investments Holdings LLC bought a new stake in shares of FibroGen in the 4th quarter worth about $530,000. DekaBank Deutsche Girozentrale increased its stake in FibroGen by 3.7% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 27,950 shares of the biopharmaceutical company's stock worth $397,000 after buying an additional 1,000 shares during the period. Virginia Retirement Systems ET AL purchased a new position in FibroGen in the 4th quarter worth about $141,000. Advisor Group Holdings Inc. increased its stake in FibroGen by 90.6% in the 4th quarter. Advisor Group Holdings Inc. now owns 8,909 shares of the biopharmaceutical company's stock worth $130,000 after buying an additional 4,236 shares during the period. Finally, Toronto Dominion Bank purchased a new position in FibroGen in the 4th quarter worth about $1,835,000. Institutional investors own 77.35% of the company's stock.
其他幾家機構投資者最近也改變了他們在fgen的頭寸。AllSpring Global Investments Holdings LLC在第四季度購買了FibroGen的新股，價值約53萬美元。德意志銀行第四季增持FibroGen股份3.7%DekaBank Deutsche Girozentale在此期間又購買了1,000股，現在擁有27,950股這家生物製藥公司的股票，價值39.7萬美元。弗吉尼亞退休系統等公司在第四季度購買了FibroGen的一個新頭寸，價值約141,000美元。Advisor Group Holdings Inc.在第四季度增持了90.6%的FibroGen股份。Advisor Group Holdings Inc.現在持有這家生物製藥公司8,909股股票，價值13萬美元，在此期間又購買了4,236股。最後，多倫多道明銀行在第四季度購買了FibroGen的一個新頭寸，價值約1，83.5萬美元。機構投資者持有該公司77.35%的股份。
FibroGen Stock Performance
FibroGen股票表現
NASDAQ FGEN opened at $14.33 on Thursday. The company has a market capitalization of $1.34 billion, a price-to-earnings ratio of -6.05 and a beta of 0.87. The company's 50-day simple moving average is $11.99 and its two-hundred day simple moving average is $12.00. FibroGen, Inc. has a one year low of $7.81 and a one year high of $16.91.
週四，納斯達克fgen的開盤價為14.33美元。該公司市值13.4億美元，市盈率為-6.05，貝塔係數為0.87。該公司的50日簡單移動均線切入位為11.99美元，200日簡單移動均線切入位為12.00美元。FibroGen，Inc.的一年低點為7.81美元，一年高位為16.91美元。
Analyst Ratings Changes
分析師評級發生變化
Several research firms recently commented on FGEN. Cowen raised their price target on shares of FibroGen to $14.00 in a research note on Monday. The Goldman Sachs Group reduced their price target on shares of FibroGen from $9.00 to $8.00 and set a "sell" rating on the stock in a research note on Tuesday, May 24th. Finally, StockNews.com downgraded shares of FibroGen from a "buy" rating to a "hold" rating in a research report on Wednesday, August 10th.
幾家研究公司最近對fgen發表了評論。考恩在週一的一份研究報告中將FibroGen的股價目標上調至14.00美元。5月24日，高盛夫婦將FibroGen的股票目標價從9.00美元下調至8.00美元，並在週二的一份研究報告中對該股設定了“賣出”評級。最後，在8月10日星期三的一份研究報告中，StockNews.com將FibroGen的股票評級從“買入”下調至“持有”。
About FibroGen
關於FibroGen
(Get Rating)
(獲取評級)
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
FibroGen，Inc.是一家生物製藥公司，發現、開發和商業化治療嚴重未得到滿足的醫療需求的療法。該公司正在開發一種口服低氧誘導因子Pro羥基酶小分子抑制劑roxadustat，該藥已在美國、歐洲、中國和日本完成了治療慢性腎臟疾病貧血的第三階段臨牀開發，並在中國完成了治療與骨髓增生異常綜合徵相關的貧血的第二/第三階段臨牀開發。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on FibroGen (FGEN)
- Which Semiconductor Stocks Are Ready For Big Price Moves?
- Miners Advance On Earnings Despite Broader Economic Challenges
- Lowe's Stands Out Amid Q2 Retail Reports
- Agilent Technologies Proves Its Worth VS Illumina
- Target's Results Cap Upside Potential For Retail Stocks
- 免費獲取StockNews.com關於FibroGen的研究報告(Fgen)
- 哪些半導體類股準備好迎接價格大幅波動？
- 儘管面臨更廣泛的經濟挑戰，礦商的收益仍在上漲
- Lowe‘s在第二季度零售報告中脱穎而出
- 安捷倫科技對Illumina證明瞭自己的價值
- 塔吉特的業績上限零售類股的上行潛力
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.
接受FibroGen Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對FibroGen和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧